Drug Trial Radar · NCT04844424
A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Apr 14, 2021
Primary completion
May 6, 2022
Study completion Jul 12, 2022
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability and food effect of a single dose of milvexian administered as direct compression (DC) oral tablets and roller compacted (RC) oral tablets compared with milvexian administered as Phase 2 oral capsules (Part 1) and of new concept tablets consisting of a single dose of milvexian administered as oral Tablet 1 and Tablet 2 compared with milvexian administered as Phase 2 oral capsules (Part 3) in healthy participants under fasting and fed conditions; to characterize the pharmacokinetics (PK) of multiple twice daily (BID) doses for 5 days of milvexian administered as DC oral tablets and Phase 2 oral capsules in healthy participants (Part 2) and to assess the effects of dosing time and food timing on the PK of single-dose of milvexian Phase 3 oral tablet formulation in healthy participants (Part 4) and to evaluate the relative bioavailability of a single dose of milvexian administered as oral film-coated DC whole tablets, oral film-coated DC tablets dispersed in water and then mixed with apple sauce, and oral film-coated DC tablets dispersed in water and administered as a suspension using a nasogastric (NG) tube in healthy participants under fasting conditions (Part 5).
Conditions
- Healthy
Interventions
MilvexianDrug
Milvexian will be administered orally or via nasogastric route as tablets or capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve of Milvexian from Time Zero to Infinity (AUC [0-Infinity])Time frame: Up to 16 months
- Part 2: Area under the Plasma Concentration-time Curve of Milvexian From Time Zero to Time of Last Quantifiable Concentration (AUC [0-Last])Time frame: Up to 16 months
- Maximum Observed Analyte Concentration (Cmax) of MilvexianTime frame: Up to 16 months
- Parts 1 and 3: AUC (0-Infinity) of Milvexian (Food effect)Time frame: Up to 16 months
- Parts 1 and 3: AUC (0-Last) of Milvexian (Food effect)Time frame: Up to 16 months
- Parts 1 and 3: Cmax of Milvexian (Food effect)Time frame: Up to 16 months
- Actual Sampling Time to Reach the Maximum Observed Analyte Concentration (Tmax) of MilvexianTime frame: Up to 16 months
- Parts 1 and 3: Tmax of Milvexian (Food effect)Time frame: Up to 16 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.